NCT03678883 2026-04-039-ING-41 in Patients With Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT03884556 2025-07-02TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced CancersTrishula Therapeutics, Inc.Phase 1 Completed56 enrolled 19 charts
NCT03997968 2024-12-24A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsCyteir Therapeutics, Inc.Phase 1/2 Completed169 enrolled
NCT01929941 2018-01-17An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesIncyte CorporationPhase 1 Terminated5 enrolled
NCT00019513 2012-03-23Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or LymphomasNational Institutes of Health Clinical Center (CC)Phase 1 Completed108 enrolled